Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 6.53%
As of Thursday, September 17, Ocular Therapeutix, Inc.’s OCUL share price has surged by 6.53%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Commentary & Analysis
Which Is a Better Investment, Ocular Therapeutix, Inc. or Trulieve Cannabis Corp. Stock?
Learn more about whether Ocular Therapeutix, Inc. or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Rosalio Madrigal
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.81%
As of Tuesday, September 08, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.81%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 5.77%
As of Friday, August 21, Ocular Therapeutix, Inc.’s OCUL share price has surged by 5.77%, which has investors questioning if this is right time to sell.Michael Rose
Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 8.91%
As of Monday, August 17, Ocular Therapeutix, Inc.’s OCUL share price has surged by 8.91%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,194.0 | $586.4 | 55% |
|
| Shares Out (Mil) | 225.0 | 43.1 | 78% |
|
| Institutional Ownership | 98.5% | 83.7% | 79% |
|
| Float (Mil) | 184.8 | 45.1 | 72% |
|
| Beta | 0.94 | 0.73 | 56% |
|
| Avg Daily Volume (000s) | 2,542 | 331 | 84% |
|
| Price Change (52-week) |
(17.9%) | 63.2% | 35% |
|
| Growth | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 24.5% | 6.7% | 86% |
|
| Net Income (5yr) | (11.3%) | (1.4%) | 28% |
|
| EPS (5yr) | 11.1% | 15.1% | 49 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (8.4%) | (15.0%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 4 | 5 | |
| Current EPS | ($0.352) | ($1.430) | ($1.454) | |
| Month Ago EPS | ($0.352) | ($1.430) | ($1.454) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.388) | ($1.550) | ($1.523) | |
| Year/Year Chg | 0.6% | 0.7% | (27.5%) | |
| Financials | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $52 | $317 | 20% |
|
| Net Income (TTM) (Mil) | ($301) | ($11) | 5% |
|
| EPS (TTM) | ($1.409) | ($0.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($238) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $208 | $5 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $76 | $6 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,348 | $515 | 44% |
|
| Valuation | OCUL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.22 | 2.51 | 75% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | OCUL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (342.3%) | 69.4% | 1% |
|
| Net Margin | (579.1%) | 2.5% | 1% |
|
| ROA | (53.7%) | (22.4%) | 11% |
|
| ROE | (73.0%) | (21.8%) | 12% |
|
| Liabilities to Assets | 22.5% | 32.4% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Ocular Therapeutix, Inc. did not pass any screens on 9/18/2026.
